Mesoblast Ltd.
- Country
- 🇦🇺Australia
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 73
- Market Cap
- -
- Website
- http://www.mesoblast.com
Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
- Conditions
- Degenerative Disc Disease
- Interventions
- Drug: Saline
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06325566
- Locations
- 🇺🇸
Cantor Spine Center at the Paley Orthopedic & Spine Institute, Fort Lauderdale, Florida, United States
🇺🇸Interventional Pain Institute, The Villages, Florida, United States
🇺🇸Vista Clinical Research, Newnan, Georgia, United States
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
- Conditions
- Degenerative Disc Disease
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 404
- Registration Number
- NCT02412735
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸Tennessee Valley Pain Consultants, Huntsville, Alabama, United States
🇺🇸Arizona Pain Specialists, Scottsdale, Arizona, United States
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
- Conditions
- Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaHodgkin's Disease
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT01854567
- Locations
- 🇺🇸
University of Miami Health System Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01851070
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Arthrocare Arthritis Care and Research PC, Gilbert, Arizona, United States
🇺🇸Triwest Research Associates, El Cajon, California, United States
Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy
- Conditions
- Diabetic NephropathyType 2 Diabetes
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01843387
- Locations
- 🇦🇺
Monash Universtiy, Clayton, Australia
🇦🇺Melbourne Renal Research Group, Melbourne, Australia
- Prev
- 1
- 2
- 3
- Next